Dose-dependent efficacy of KF41399 on ACNU-induced thrombocytopenia
| Dose (mg/kg) . | Day 0 . | Day 4 . | Day 7 . | Day 9 . | Day 11 . | Day 14 . | Day 17 . | Day 21 . |
|---|---|---|---|---|---|---|---|---|
| Control | 101.0 ± 5.3 | 88.2 ± 4.3 | 98.7 ± 7.0 | 97.4 ± 8.3 | 96.3 ± 8.9 | 99.7 ± 4.5 | 98.2 ± 5.1 | 94.3 ± 8.1 |
| 0.2 | 90.5 ± 17.3 | 95.2 ± 2.9 | 80.6 ± 10.7 | 32.3 ± 5.8 | 11.8 ± 4.6 | 12.4 ± 13.1 | 23.2 ± 21.3 | 31.4 ± 19.0 |
| 1 | 95.9 ± 11.1 | 87.4 ± 11.2 | 82.3 ± 2.1 | 34.3 ± 0.6 | 14.2 ± 3.6 | 28.2 ± 15.2 | 62.8 ± 32.4 | 61.4 ± 32.3 |
| 5 | 113.4 ± 6.3 | 94.0 ± 2.8 | 91.73-150 ± 5.0 | 69.43-150 ± 11.4 | 39.43-150 ± 6.9 | 65.63-150 ± 12.9 | 69.23-150 ± 12.2 | 72.4 ± 12.1 |
| 25 | 102.7 ± 13.0 | 93.6 ± 3.6 | 107.03-150 ± 11.9 | 96.83-150 ± 10.2 | 54.13-150 ± 10.1 | 54.13-150 ± 10.1 | 66.03-150 ± 8.3 | 83.6 ± 13.8 |
| ACNU | 100.9 ± 11.1 | 88.8 ± 6.1 | 78.83-150 ± 2.0 | 28.03-150 ± 8.5 | 9.03-150 ± 3.0 | 17.53-150 ± 13.7 | 35.93-150 ± 26.2 | 59.0 ± 31.5 |
| Dose (mg/kg) . | Day 0 . | Day 4 . | Day 7 . | Day 9 . | Day 11 . | Day 14 . | Day 17 . | Day 21 . |
|---|---|---|---|---|---|---|---|---|
| Control | 101.0 ± 5.3 | 88.2 ± 4.3 | 98.7 ± 7.0 | 97.4 ± 8.3 | 96.3 ± 8.9 | 99.7 ± 4.5 | 98.2 ± 5.1 | 94.3 ± 8.1 |
| 0.2 | 90.5 ± 17.3 | 95.2 ± 2.9 | 80.6 ± 10.7 | 32.3 ± 5.8 | 11.8 ± 4.6 | 12.4 ± 13.1 | 23.2 ± 21.3 | 31.4 ± 19.0 |
| 1 | 95.9 ± 11.1 | 87.4 ± 11.2 | 82.3 ± 2.1 | 34.3 ± 0.6 | 14.2 ± 3.6 | 28.2 ± 15.2 | 62.8 ± 32.4 | 61.4 ± 32.3 |
| 5 | 113.4 ± 6.3 | 94.0 ± 2.8 | 91.73-150 ± 5.0 | 69.43-150 ± 11.4 | 39.43-150 ± 6.9 | 65.63-150 ± 12.9 | 69.23-150 ± 12.2 | 72.4 ± 12.1 |
| 25 | 102.7 ± 13.0 | 93.6 ± 3.6 | 107.03-150 ± 11.9 | 96.83-150 ± 10.2 | 54.13-150 ± 10.1 | 54.13-150 ± 10.1 | 66.03-150 ± 8.3 | 83.6 ± 13.8 |
| ACNU | 100.9 ± 11.1 | 88.8 ± 6.1 | 78.83-150 ± 2.0 | 28.03-150 ± 8.5 | 9.03-150 ± 3.0 | 17.53-150 ± 13.7 | 35.93-150 ± 26.2 | 59.0 ± 31.5 |
Various doses of KF41399 and ACNU were administered according to the schedule of protocol G in Table 1. ACNU was administered according to the schedule of protocol I in Table 1, and peripheral platelet counts were analyzed as described in “Materials and methods.” Results are expressed as mean ± SD.
N = 5 in each group.
P < .05.